Lung cancer remains a major cause of morbidity and mortality worldwide, accounting for more deaths than any other cancer cause. Lung cancer has been the most common cancer in the world for several decades. Risk factors for lung cancer are smoking, genetic mutation/predisposition, and occupational/environmental exposure. Biosimilarity of a monoclonal antibody can be established by demonstrating comparable clinical efficacy of the biosimilar and the reference medicinal product in adequately powered, randomised, parallel group comparative clinical trial(s), by using efficacy end points in a study population that is representative of approved therapeutic indication(s) of the reference product and is sensitive for detecting potential differences between the biosimilar and the reference product. To establish the biosimilarity between the test and reference bevacizumab, Intas Pharmaceuticals Limited, India will be conducting this comparative clinical study with the aim of comparing the efficacy and safety of INTP24 (biosimilar bevacizumab) with that of Avastin (Roche Registration Limited, United Kingdom) in patients with advanced, unresectable or metastatic non-squamous non-small cell lung cancer. The study will be a randomized, double-blind, multicentre, multinational, parallelgroup, active-controlled, comparative clinical trial. The study will enrol female or male patients aged greater than or equal to 18 years and having histologically or cytologically-confirmed locally advanced, unresectable or recurrent or metastatic non-squamous non-small cell lung cancer with Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. Each enrolled patients will be randomized to receive either bevacizumab manufactured by Intas Pharmaceuticals Limited, India or Avastin of Roche Registration Limited, United Kingdom as per randomization schedule generated. All patients will receive intravenous injection of 15 mg/kg of bevacizumab in 21-day cycles. 594 patients will be enrolled.